Mycophenolic acid plasma trough level: correlation with clinical outcome

Area of Science:

• Nephrology
• Immunosuppression Therapy
• Pharmacokinetics

Background:

• Mycophenolate mofetil (MMF) is a key immunosuppressant in renal transplantation.
• Monitoring mycophenolic acid (MPA) plasma trough levels (MPACmin) is common practice.
• The relationship between MPACmin, MMF dosage, and clinical outcomes requires further investigation.

Purpose of the Study:

• To assess the correlation between MPACmin, MMF dosage, and immunosuppression status.
• To evaluate the association between these parameters and clinical outcomes, including acute rejection, in renal transplant recipients.

Main Methods:

• MPACmin were measured in 30 kidney transplant patients.
• Patients were categorized based on graft function (acute rejection vs. normal).
• Graft outcome was compared against MPACmin, MMF dosage, and lymphocyte count (LC).

Main Results:

• No significant differences in MPACmin, MMF dosage, or LC were found between patients with acute rejection and those with normal graft function.
• Acute rejection rates were higher with a 1-g MMF dose compared to 1.5-g or 2-g doses.
• No correlation was observed between MPACmin and MMF dosage, nor with LC.

Conclusions:

• MPACmin is a poor indicator of clinical outcome and immunosuppression status in renal transplant patients.
• While the standard 2-g MMF dose may be associated with rejection, a lower 1-g dose appears to carry a higher risk.